Hacker Newsnew | past | comments | ask | show | jobs | submitlogin

Great cause. Why is industry not interested in developing 9-deoxysibiromycin as a drug?


unpatentable. Check the date:

https://www.ncbi.nlm.nih.gov/pubmed/22390171

Also the mechanism of action is baroque (although the compound class has fewer side effects), standard pharma is mostly interested in flashy new types of anticancer mechanisms.




Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: